UnitedHealthcare Ozempic or GLP-1 Denied? Weight Loss Drug Appeal

GLP-1 receptor agonists like Ozempic (semaglutide), Wegovy (semaglutide), Mounjaro (tirzepatide), and Zepbound (tirzepatide) have become the most sought-after drugs in America — and also some of the most frequently denied. UnitedHealthcare's coverage decisions for these medications are complex, and a denial is not the end of the road. Here is exactly how UHC evaluates these drugs and how to appeal effectively.

Why UnitedHealthcare Denies GLP-1 Claims

UHC denies GLP-1 prescriptions for several different reasons depending on the specific drug, the indication, and the plan type:

• Prior Authorization Denied: How to Appeal" class="auto-link">Prior authorization criteria not met: UHC requires specific BMI thresholds and/or documented comorbidities before approving GLP-1s
• Step therapy required: UHC mandates that other medications (typically metformin for type 2 diabetes, or other drugs) be tried and failed before GLP-1s are authorized
• Formulary tier placement: GLP-1s are placed on high-cost tiers, and the "denial" is actually a cost-sharing issue rather than a coverage exclusion
• Weight loss exclusion: Many employer plans exclude FDA-approved weight loss medications entirely — Wegovy and Zepbound are approved specifically for obesity, while Ozempic and Mounjaro are approved for type 2 diabetes
• Off-label use: UHC denies GLP-1s prescribed for PCOS, NAFLD, or other off-label indications that are not listed in their coverage criteria
• Plan does not cover obesity drugs: As of 2024, Medicare Part D still does not cover GLP-1s solely for obesity (only for covered cardiovascular indications or diabetes)

UHC's Formulary Tiers and Step Therapy Requirements

UHC places GLP-1 medications on specialty tier formulary positions (Tier 4 or 5 in most commercial plans), which means high cost-sharing even when covered. Understanding your specific plan's formulary is the first step.

For type 2 diabetes indications (Ozempic, Mounjaro), UHC's prior authorization criteria typically require:

• HbA1c ≥7.0% (or ≥6.5% in some plans) confirming diabetes diagnosis
• Metformin trial: Documentation that metformin was tried at maximum tolerated dose for a specified period (often 90 days), unless metformin is contraindicated
• Step therapy documentation: In some plans, a second-line agent (SGLT-2 inhibitor or sulfonylurea) must also be tried before GLP-1 is authorized

For obesity indications (Wegovy, Zepbound), UHC's prior authorization criteria typically require:

• BMI ≥30, OR
• BMI ≥27 with at least one weight-related comorbidity (hypertension, type 2 diabetes, dyslipidemia, sleep apnea, or cardiovascular disease)
• Documentation of prior weight loss program participation (diet, exercise, behavioral therapy)
• Prescription from a physician (not just any provider in some plans)

2024 Regulatory Changes: Medicare and GLP-1 Coverage

In November 2023, CMS issued a final rule allowing Medicare Part D plans to cover GLP-1 drugs when prescribed for FDA-approved cardiovascular risk reduction — not solely for obesity or weight loss. Specifically, semaglutide (Wegovy) received FDA approval in March 2024 for reducing cardiovascular risk in people with obesity and established cardiovascular disease (CVD).

This means: if your Medicare Advantage or Part D plan denied Wegovy for obesity, but you have established cardiovascular disease and your cardiologist prescribes it for CV risk reduction, the denial may be improper under the new CMS guidance. The prescription indication matters significantly.

Additionally, as of 2025, many state Medicaid programs have begun covering GLP-1s for obesity. Check your state's specific Medicaid formulary.

Your Legal Rights

• Step therapy override laws: Over 30 states have enacted laws requiring insurers to honor step therapy exceptions when the standard drugs are contraindicated or when a patient has previously failed them. If you tried metformin and it was ineffective or caused intolerable side effects, document this in detail.
• ERISA plans: Self-funded employer plans are subject to fewer state laws but must still provide a full and fair review under ERISA. Evidence-based medical necessity arguments remain applicable.
• ACA essential health benefits: GLP-1 drugs for diabetes fall within the prescription drug EHB category in marketplace plans.

Exact Appeal Steps With UnitedHealthcare

1. Call 1-866-892-5890 to initiate your appeal and confirm the specific PA criteria used in your denial.
2. Request UHC's pharmacy clinical coverage criteria for the specific GLP-1 drug prescribed.
3. Have your prescribing physician provide documentation:
   • For diabetes: HbA1c results, metformin trial documentation, clinical rationale for GLP-1
   • For obesity: BMI measurement, comorbidities with supporting labs/diagnoses, prior weight management program documentation
4. File your appeal within 180 days with the prescription, physician's letter, and all supporting clinical records.
5. Invoke step therapy exception if prior drugs were tried and failed — cite your state's step therapy override law by name if applicable.
6. Request External Independent Review: Complete Guide" class="auto-link">external review if internal appeal is denied.

What to Include in Your Appeal Letter

• Physician's letter addressing UHC's specific PA criteria point by point
• Lab results: HbA1c, lipid panel, blood pressure readings, sleep study (if sleep apnea is a comorbidity)
• BMI documentation: Height, weight, calculated BMI from a clinical encounter — not self-reported
• Comorbidity diagnoses: Official diagnosis codes from treating physicians for all weight-related comorbidities
• Prior therapy documentation: Prescriptions, pharmacy records, and clinical notes showing drugs tried and why they were insufficient
• For cardiovascular indication: Cardiology records confirming established CVD and prescribing letter for CV risk reduction indication
• State step therapy law citation if applicable

Formulary Exception Request

Before or alongside your appeal, request a formulary exception — a separate process from a PA appeal. Formulary exceptions are appropriate when:

• The formulary drugs for your condition are contraindicated for you
• You have tried formulary alternatives and they were ineffective
• Your physician certifies that the requested drug is medically necessary for your condition

A successful formulary exception can move the GLP-1 to a lower cost tier and resolve the affordability issue independently of the medical necessity question.

Why Many GLP-1 Appeals Succeed

GLP-1 appeals succeed most often when step therapy exceptions are documented (prior drugs tried and failed), when diabetes indications are clear and HbA1c thresholds are met, or when cardiovascular indication documentation is complete. Appeals for obesity-only indications on plans with explicit exclusions are harder — but employer plan exceptions and state step therapy laws provide alternative pathways.

Fight Back With ClaimBack

A GLP-1 denial does not have to mean years of waiting for metabolic care. ClaimBack helps you build an evidence-based appeal citing UHC's PA criteria, your clinical documentation, and applicable step therapy or state laws. Start your appeal at https://claimback.app/appeal.

Related Reading

• How to Write an Insurance Appeal Letter
• What Is Medical Necessity?
• Internal vs External Insurance Appeal